Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases

Human papillomavirus (HPV) has long been recognized as the causative agent of cervical cancer. High-risk HPV types 16 and 18 alone are responsible for over 70% of all cases of cervical cancers. More recently, HPV has been identified as an etiological factor for several other forms of cancers, including oropharyngeal, anogenital, and skin. Thus, the association of HPV with these malignancies creates an opportunity to control these HPV lesions and HPV-associated malignancies through immunization. Strategies to prevent or to therapeutically treat HPV infections have been developed and are still pushing innovative boundaries. Currently, commercial prophylactic HPV vaccines are widely available, but they are not able to control established infections or lesions. As a result, there is an urgent need for the development of therapeutic HPV vaccines, to treat existing infections, and to prevent the development of HPV-associated cancers. In particular, DNA vaccination has emerged as a promising form of therapeutic HPV vaccine. DNA vaccines have great potential for the treatment of HPV infections and HPV-associated cancers due to their safety, stability, simplicity of manufacturability, and ability to induce antigen-specific immunity. This review focuses on the current state of therapeutic HPV DNA vaccines, including results from recent and ongoing clinical trials, and outlines different strategies that have been employed to improve their potencies. The continued progress and improvements made in therapeutic HPV DNA vaccine development holds great potential for innovative ways to effectively treat HPV infections and HPV-associated diseases.

• Publication year

  2018

• Venue

  Human Gene Therapy

• Publication date

  2018-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/hum.2017.197PMID 29316817PMCID PMC6152857
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A plant protein signal sequence improved humoral immune response to HPV prophylactic and therapeutic DNA vaccines

  2017cited by this paper
• Immunogenicity results using human papillomavirus (HPV) specific DNA vaccine, INO-3112 (HPV16/HPV18 plasmids + IL-12) in HPV+ head and neck squamous cell carcinoma (HNSCCa).

  2017cited by this paper
• Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11–001

  2017cited by this paper
• DNA vaccine encoding human papillomavirus antigens flanked by a signal peptide and a KDEL sequence induces a potent therapeutic antitumor effect

  2017cited by this paper
• Cervical cancer: A global health crisis

  2017cited by this paper
• Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence

  2017cited by this paper
• The current state of therapeutic and T cell-based vaccines against human papillomaviruses.

  2017cited by this paper
• Review of HPV-related diseases and cancers.

  2017cited by this paper
• DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection

  2017cited by this paper
• Enhancing antitumor immunogenicity of HPV16-E7 DNA vaccine by fusing DNA encoding E7-antigenic peptide to DNA encoding capsid protein L1 of Bovine papillomavirus

  2017cited by this paper
• Enhanced anti-tumor therapeutic efficacy of DNA vaccine by fusing the E7 gene to BAFF in treating human papillomavirus-associated cancer

  2017cited by this paper
• Current state in the development of candidate therapeutic HPV vaccines

  2016cited by this paper
• Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies

  2016cited by this paper
• A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3).

  2016cited by this paper
• Human papillomavirus-associated cancers: A growing global problem

  2016cited by this paper
• Perspectives for therapeutic HPV vaccine development

  2016cited by this paper
• Intravaginal Administration of Fc-Fused IL7 Suppresses the Cervicovaginal Tumor by Recruiting HPV DNA Vaccine-Induced CD8 T Cells

  2016cited by this paper
• Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100

  2016cited by this paper
• CD28 Costimulation: From Mechanism to Therapy.

  2016cited by this paper
• Activated STING enhances Tregs infiltration in the HPV-related carcinogenesis of tongue squamous cells via the c-jun/CCL22 signal.

  2015cited by this paper
• Regulatory T cell memory

  2015cited by this paper
• A novel RNA‐based adjuvant combines strong immunostimulatory capacities with a favorable safety profile

  2015cited by this paper
• Human Papillomaviruses; Epithelial Tropisms, and the Development of Neoplasia

  2015cited by this paper
• Human papillomavirus molecular biology and disease association

  2015cited by this paper
• Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study

  2015cited by this paper
• A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.

  2015cited by this paper
• Stat1-Deficient Mice Are Not an Appropriate Model for Efficacy Testing of Recombinant Vesicular Stomatitis Virus-Based Filovirus Vaccines.

  2015cited by this paper
• Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

  2015cited by this paper
• Self-adjuvanting lipoimmunogens for therapeutic HPV vaccine development: potential clinical impact

  2015cited by this paper
• Intravaginal HPV DNA vaccination with electroporation induces local CD8+ T-cell immune responses and antitumor effects against cervicovaginal tumors

  2015influential reference
• Gardasil 9 joins the fight against cervix cancer

  2015cited by this paper
• Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine

  2015cited by this paper
• A DNA vaccine encoding mutated HPV58 mE6E7-Fc-GPI fusion antigen and GM-CSF and B7.1

  2015cited by this paper
• Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus

  2015cited by this paper
• Next generation prophylactic human papillomavirus vaccines.

  2015cited by this paper
• Local administration of granulocyte macrophage colony-stimulating factor induces local accumulation of dendritic cells and antigen-specific CD8+ T cells and enhances dendritic cell cross-presentation.

  2015cited by this paper
• Evolution of electroporated DNA vaccines.

  2014cited by this paper
• Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients

  2014cited by this paper
• Therapeutic Vaccine Strategies against Human Papillomavirus

  2014cited by this paper
• Comparing the effect of Toll-like receptor agonist adjuvants on the efficiency of a DNA vaccine

  2014cited by this paper
• Encoded novel forms of HSP70 or a cytolytic protein increase DNA vaccine potency

  2014cited by this paper
• HPV-associated diseases.

  2014cited by this paper
• Fusion of CTLA-4 with HPV16 E7 and E6 Enhanced the Potency of Therapeutic HPV DNA Vaccine

  2014cited by this paper
• Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity.

  2014cited by this paper
• Overexpression of Calreticulin Contributes to the Development and Progression of Pancreatic Cancer

  2014cited by this paper
• Intramuscular Therapeutic Vaccination Targeting HPV16 Induces T Cell Responses That Localize in Mucosal Lesions

  2014cited by this paper
• The Burden of HPV-Associated Anogenital Cancers

  2014cited by this paper
• Antitumor effect of therapeutic HPV DNA vaccines with chitosan-based nanodelivery systems

  2014cited by this paper
• Histone deacetylase inhibitor AR-42 enhances E7-specific CD8+ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination

  2013cited by this paper
• HSP70 modified response against HPV based tumor.

  2013cited by this paper
• Virus-like particles for the prevention of human papillomavirus-associated malignancies

  2013cited by this paper
• Electroporation mediated DNA vaccination directly to a mucosal surface results in improved immune responses

  2013influential reference
• Combined Stimulation of IL-2 and 4-1BB Receptors Augments the Antitumor Activity of E7 DNA Vaccines by Increasing Ag-Specific CTL Responses

  2013cited by this paper
• Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections.

  2013cited by this paper
• Synthetic DNA Vaccines: Improved Vaccine Potency by Electroporation and Co-Delivered Genetic Adjuvants

  2013influential reference
• L2, the minor capsid protein of papillomavirus.

  2013cited by this paper
• Induction of robust cellular immunity against HPV6 and HPV11 in mice by DNA vaccine encoding for E6/E7 antigen

  2012cited by this paper
• Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine

  2012cited by this paper
• Emerging human papillomavirus vaccines

  2012cited by this paper
• EUROGIN 2011 roadmap on prevention and treatment of HPV‐related disease

  2012cited by this paper
• Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy.

  2012cited by this paper
• Overexpression of Calreticulin in Malignant and Benign Breast Tumors: Relationship with Humoral Immunity

  2012cited by this paper
• Global burden of human papillomavirus and related diseases.

  2012cited by this paper
• Whole cell vaccines--past progress and future strategies.

  2012cited by this paper
• Cross-presentation by dendritic cells

  2012cited by this paper
• Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells.

  2012cited by this paper
• Therapeutic vaccination against human papilloma virus induced malignancies.

  2011cited by this paper
• Towards a systems understanding of MHC class I and MHC class II antigen presentation

  2011cited by this paper
• Enhancement of DNA vaccine potency by antigen linkage to IFN‐γ‐inducible protein‐10

  2011cited by this paper
• TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway.

  2011cited by this paper
• Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7

  2011influential reference
• Enhancement of Vaccine-induced Primary and Memory CD8+ T-cell Responses by Soluble PD-1

  2011cited by this paper
• Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy.

  2011cited by this paper
• Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines

  2011cited by this paper
• Molecular pathogenesis of cervical cancer

  2011cited by this paper
• Prevention and treatment of papillomavirus-related cancers through immunization.

  2011cited by this paper
• DNA Immunization with Fusion of CTLA-4 to Hepatitis B Virus (HBV) Core Protein Enhanced Th2 Type Responses and Cleared HBV with an Accelerated Kinetic

  2011cited by this paper
• Perspectives for preventive and therapeutic HPV vaccines.

  2010cited by this paper
• Therapeutic HPV DNA vaccines

  2010influential reference
• An HDAC inhibitor enhances the antitumor activity of a CMV promoter-driven DNA vaccine

  2010cited by this paper
• Innovative DNA Vaccine for Human Papillomavirus (HPV)-Associated Head and Neck Cancer

  2010influential reference
• Treatment with Imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination

  2010cited by this paper
• Human papillomavirus: gene expression, regulation and prospects for novel diagnostic methods and antiviral therapies.

  2010cited by this paper
• Dendritic Cell Apoptosis: Regulation of Tolerance versus Immunity

  2010cited by this paper
• Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.

  2010cited by this paper
• Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies.

  2010cited by this paper
• Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+CD25+ T regulatory cells.

  2009cited by this paper
• Enhancing DNA vaccine potency by co-administration of xenogenic MHC-class-I DNA

  2009cited by this paper
• Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer.

  2009cited by this paper
• Murine epidermal Langerhans cells and langerin-expressing dermal dendritic cells are unrelated and exhibit distinct functions

  2009cited by this paper
• The efficiency of a novel delivery system (PEI600-Tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen

  2009cited by this paper
• Treatment with demethylating agent, 5-aza-2'-deoxycytidine enhances therapeutic HPV DNA vaccine potency.

  2009cited by this paper
• Femtosecond laser treatment enhances DNA transfection efficiency in vivo

  2009cited by this paper
• A Phase I Trial of a Human Papillomavirus DNA Vaccine for HPV16+ Cervical Intraepithelial Neoplasia 2/3

  2009cited by this paper
• Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery.

  2009cited by this paper
• Interleukin-33 - cytokine of dual function or novel alarmin?

  2009cited by this paper
• Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts

  2009cited by this paper
• Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects

  2009cited by this paper

• Investigation of the presence of cervical human papillomavirus and the distribution of preinvasive lesions in patients using immunomodulators-Inosine Pranobex

  2026cites this paper
• Human papillomavirus infection and vaccination with thyroid diseases: mechanistic links and immunological insights

  2025cites this paper
• Advances in Therapeutic Vaccines Against HPV: A Review of Human Clinical Trials

  2025cites this paper
• Visual clues — dermatological manifestations of sexually transmitted infections in men

  2025cites this paper
• DNA Vaccine Technologies: Design and Delivery

  2025cites this paper
• Harnessing nano-delivery systems to un-cover the challenges for cervical cancer therapy.

  2025cites this paper
• In Situ Cancer Vaccines: Redefining Immune Activation in the Tumor Microenvironment.

  2025cites this paper
• Human papillomavirus type 16 and 18 viral clearance and progression to precancer among women aged 18–25 years enrolled in the Costa Rica HPV prophylactic vaccine trial (CVT)

  2025cites this paper
• Unraveling HPV-associated cancer complexity: From molecular insights to innovative therapies

  2025cites this paper
• Augmented immunogenicity of the HPV16 DNA vaccine via dual adjuvant approach: integration of CpG ODN into plasmid backbone and co-administration with IL-28B gene adjuvant

  2025cites this paper
• Investigation of the Potency of KALA and REV Cell‐Penetrating Peptides for In Vitro/In Vivo Delivery of an HPV Multiepitope DNA Construct

  2025cites this paper
• Novel prophylactic and therapeutic multi-epitope vaccine based on Ag85A, Ag85B, ESAT-6, and CFP-10 of Mycobacterium tuberculosis using an immunoinformatics approach

  2024cites this paper
• Electroporation-mediated novel albumin-fused Flt3L DNA delivery promotes cDC1-associated anticancer immunity

  2024cites this paper
• Targeting HPV for the prevention, diagnosis, and treatment of cervical cancer

  2024cites this paper
• A phase Ib study to assess the safety of the human papillomavirus DNA vaccine (AMV002) in combination with durvalumab for HPV-associated oropharyngeal squamous cell carcinoma

  2024cites this paper
• Oral HPV infection clearance and acquisition after nonavalent vaccination in men who have sex with men and transgender women: a prospective analysis

  2024cites this paper
• Metal-based approaches to fight cervical cancer.

  2024cites this paper
• Structure and transcription of integrated HPV DNA in vulvar carcinomas

  2024cites this paper
• Preclinical Immunogenicity and Efficacy Studies for Therapeutic Vaccines for Human Papillomavirus-Type-16-Associated Cancer

  2024cites this paper
• Development of an mRNA-based therapeutic vaccine mHTV-03E2 for high-risk HPV-related malignancies.

  2024cites this paper
• Human Papillomavirus Vaccines

  2023cites this paper
• mRNA‐HPV vaccine encoding E6 and E7 improves therapeutic potential for HPV‐mediated cancers via subcutaneous immunization

  2023cites this paper
• A Comprehensive View of the Cancer-Immunity Cycle (CIC) in HPV-Mediated Cervical Cancer and Prospects for Emerging Therapeutic Opportunities

  2023cites this paper
• DNA Vaccines: History, Molecular Mechanisms and Future Perspectives.

  2023cites this paper
• Epidemiology, Molecular Pathogenesis, Immuno-Pathogenesis, Immune Escape Mechanisms and Vaccine Evaluation for HPV-Associated Carcinogenesis

  2023cites this paper
• Vaccines for HPV-associated diseases.

  2023cites this paper
• A replicative recombinant HPV16 E7 expression virus upregulates CD36 in C33A cells

  2023cites this paper
• Prophylactic HPV vaccines in patients with HPV-associated diseases and cancer.

  2023cites this paper
• Progress Towards a Therapeutic HIV DNA Vaccine

  2022cites this paper
• Human Papilloma Virus Vaccination and Oropharyngeal Cancer: Knowledge, Perception and Attitude among Italian Pediatric Dentists

  2022cites this paper
• Photosensitizer-induced HPV16 E7 nanovaccines for cervical cancer immunotherapy.

  2022cites this paper
• Immunotherapeutic approaches for HPV-caused cervical cancer.

  2022cites this paper
• Development of DNA Vaccine Candidate against SARS-CoV-2

  2022cites this paper
• The Effectiveness of Therapeutic Vaccines for the Treatment of Cervical Intraepithelial Neoplasia 3: A Systematic Review and Meta-Analysis

  2022cites this paper
• Alternative strategies for Chlamydia treatment: Promising non-antibiotic approaches

  2022cites this paper
• Toward QbD Process Understanding on DNA Vaccine Purification Using Design of Experiment

  2021influential citation
• Virus against virus: strategies for using adenovirus vectors in the treatment of HPV-induced cervical cancer

  2021cites this paper
• Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody

  2021cites this paper
• Vaccine Strategies for Human Papillomavirus-Associated Head and Neck Cancers

  2021cites this paper
• Design of Experiments to Achieve an Efficient Chitosan-Based DNA Vaccine Delivery System

  2021cites this paper
• Advances in Engineered Polymer Nanoparticle Tracking Platforms towards Cancer Immunotherapy—Current Status and Future Perspectives

  2021cites this paper
• A review on the advances and challenges of immunotherapy for head and neck cancer

  2021cites this paper
• Physiopathology and effectiveness of therapeutic vaccines against human papillomavirus

  2021cites this paper
• Recombinant Antigens E6 and E7 of Human Papilloma Virus Type 16: Preparation, Purification, and Assessment of the Immunogenicity and Antitumor Effects In Vivo

  2021cites this paper
• The Efficacy of Therapeutic DNA Vaccines Expressing the Human Papillomavirus E6 and E7 Oncoproteins for Treatment of Cervical Cancer: Systematic Review

  2021cites this paper
• Natural and vaccine-induced B cell-derived systemic and mucosal humoral immunity to human papillomavirus

  2020influential citation
• Inhibition of antigen-specific immune responses by co-application of an indoleamine 2,3-dioxygenase (IDO)-encoding vector requires antigen transgene expression focused on dendritic cells

  2020cites this paper
• Design of a multi-epitope protein vaccine against herpes simplex virus, human papillomavirus and Chlamydia trachomatis as the main causes of sexually transmitted diseases.

  2020cites this paper
• Vaccination Strategies for the Control and Treatment of HPV Infection and HPV-Associated Cancer.

  2020cites this paper
• Plant-Derived Natural Compounds in Genetic Vaccination and Therapy for HPV-Associated Cancers

  2020cites this paper
• Process Characterization by Definitive Screening Design Approach on DNA Vaccine Production

  2020cites this paper
• A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC)

  2020cites this paper
• A novel concept for treatment and vaccination against Covid‐19 with an inhaled chitosan‐coated DNA vaccine encoding a secreted spike protein portion

  2020cites this paper
• Regulatory Considerations on the Development of mRNA Vaccines.

  2020cites this paper
• A Phase I trial assessing the safety and tolerability of a therapeutic DNA vaccination against HPV16 and HPV18 E6/E7 oncogenes after chemoradiation for cervical cancer.

  2020cites this paper
• A DNA Vaccine Encoding SA-4-1BBL Fused to HPV-16 E7 Antigen Has Prophylactic and Therapeutic Efficacy in a Cervical Cancer Mouse Model

  2019cites this paper
• Vulvar Disease: Breaking the Myths

  2019cites this paper
• Expression of p16 and p53 in non-small-cell lung cancer: clinicopathological correlation and potential prognostic impact.

  2019cites this paper
• Endoplasmic reticulum stress enhances the antigen-specific T cell immune responses and therapeutic antitumor effects generated by therapeutic HPV vaccines

  2019cites this paper
• Nonsurgical Treatment of Preneoplastic Vulvar Conditions

  2019cites this paper
• HPV Vaccination Concepts in the Reality of Today

  2019cites this paper
• Anti-Cancer Vaccine for HPV-Associated Neoplasms: Focus on a Therapeutic HPV Vaccine Based on a Novel Tumor Antigen Delivery Method Using Endogenously Engineered Exosomes

  2019cites this paper
• DNA Vaccination in 2018: An Update

  2018cites this paper
• Antigens for DNA Vaccines Against Tuberculosis

  2018cites this paper
• Plasmid-Based DNA Vaccines

  2018cites this paper